- Home
- PROK vs PDSB Comparison
PROK vs PDSB Comparison
Compare PROK & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- PDSB
- Stock Information
- Founded
- PROK 2015
- PDSB 2005
- Country
- PROK United States
- PDSB United States
- Employees
- PROK N/A
- PDSB N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- PDSB Health Care
- Exchange
- PROK Nasdaq
- PDSB Nasdaq
- Market Cap
- PROK 85.5M
- PDSB 72.2M
- IPO Year
- PROK N/A
- PDSB N/A
- Fundamental
- Price
- PROK $4.74
- PDSB $1.24
- Analyst Decision
- PROK Buy
- PDSB Strong Buy
- Analyst Count
- PROK 4
- PDSB 2
- Target Price
- PROK $5.33
- PDSB $10.00
- AVG Volume (30 Days)
- PROK 33.1M
- PDSB 473.1K
- Earning Date
- PROK 08-08-2025
- PDSB 08-12-2025
- Dividend Yield
- PROK N/A
- PDSB N/A
- EPS Growth
- PROK N/A
- PDSB N/A
- EPS
- PROK N/A
- PDSB N/A
- Revenue
- PROK $306,000.00
- PDSB N/A
- Revenue This Year
- PROK $54.34
- PDSB N/A
- Revenue Next Year
- PROK N/A
- PDSB N/A
- P/E Ratio
- PROK N/A
- PDSB N/A
- Revenue Growth
- PROK N/A
- PDSB N/A
- 52 Week Low
- PROK $0.46
- PDSB $0.85
- 52 Week High
- PROK $7.13
- PDSB $4.42
- Technical
- Relative Strength Index (RSI)
- PROK 92.14
- PDSB 39.29
- Support Level
- PROK $0.54
- PDSB $1.20
- Resistance Level
- PROK $7.13
- PDSB $1.40
- Average True Range (ATR)
- PROK 0.62
- PDSB 0.10
- MACD
- PROK 0.47
- PDSB -0.03
- Stochastic Oscillator
- PROK 68.59
- PDSB 12.50
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.